AI-Powered Detection of Lymph Node Metastasis in Breast Tumor Resections

Singapore, April 30, 2024 — Qritive participated in the USCAP 113th Annual Meeting with multiple studies demonstrating the clinical value of AI-powered pathology applications in cancer diagnostics.

A Deep Learning Module to Assist Pathologists in Identifying Lymph Node Metastasis in Breast Tumor Resections

USCAP 113th Annual Meeting | March 23–28, 2024 | Baltimore, MD

This study highlights the development and evaluation of an AI module designed to assist pathologists in detecting lymph node metastases—particularly micrometastasis—in breast tumor resections.

Using a segmentation-based deep learning approach, the model demonstrated the ability to significantly reduce the time required for reviewing slides, while also improving sensitivity in detecting both micro- and macrometastases. The study underscores the clinical value of integrating AI into routine pathology workflows to enhance speed, accuracy, and diagnostic confidence.

View Abstract on USCAP Website

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com